A unifying theory for the pathoetiologic mechanism of tardive dyskinesia

Ziad Ali1, Autumn Roque2, Rif S El-Mallakh1

  • 1Mood Disorders Research Program, Depression Center, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, United States.

Medical Hypotheses
|March 23, 2020
PubMed
Abstract

Insights

Tardive dyskinesia (TD) may stem from complex synaptic changes, not just dopamine receptor supersensitivity. This suggests "synaptic upregulation" is a more accurate term for these neurobiological alterations.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Chronic dopamine D2 receptor antagonist treatment is thought to cause dopamine receptor supersensitivity.
  • Existing models of receptor supersensitivity, like D2 receptor upregulation, don't fully explain conditions such as tardive dyskinesia (TD).

Purpose of the Study:

  • To investigate the neurobiological underpinnings of TD beyond simple dopamine receptor supersensitivity.
  • To propose a more accurate terminology for the observed changes.

Main Methods:

  • Review of recent data on TD mechanisms.
  • Analysis of presynaptic, synaptic, and postsynaptic changes in animal models and clinical observations.

Main Results:

  • Presynaptic dopamine release increases due to dopamine transporter reuptake of unbound dopamine.
  • Synaptic alterations, including perforated synapses, indicate new synapse formation.
  • Postsynaptic D2 receptor expression increases, but without enhanced sensitivity or potency.

Conclusions:

  • TD development involves multifaceted changes across the synapse.
  • 'Synaptic upregulation' may be a more fitting term than 'dopamine receptor supersensitivity'.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
1.7K
Mechanism of Ciliary Motion01:05

Mechanism of Ciliary Motion

The ciliary structures were first seen in 1647 by Antonie Leeuwenhoek while observing the protozoans. In lower organisms, these appendages are responsible for cell movement, while in higher organisms, these appendages help in the movement of the extracellular fluids within the body cavities.
The cilia are made up of microtubules in a 9+2 arrangement, with nine microtubule doublet ring bundles, surrounding a pair of central singlet microtubule bundles. The doublet microtubule bundles are...
4.6K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
867
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.4K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.0K